Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

To join this study, you must be at least 18 years old and have a confirmed diagnosis of limited-stage small cell lung cancer. You must have already completed a standard course of chemotherapy and radiation treatment for your cancer and these treatments should not have caused your cancer to get worse.

Your general health and physical ability should be good, as assessed by the healthcare team. There are also specific requirements regarding your organ function, which the study doctors will check. If you have certain other medical conditions, like some autoimmune diseases, or if you have already received other types of lung cancer treatment beyond your initial chemotherapy and radiation, you might not be able to participate.

If you decide to take part in this study, you will be given one of the study drugs (toripalimab, tifcemalimab, both, or a placebo) as an injection. This will start within 42 days after your last chemotherapy treatment. The study will involve regular visits to the clinic for treatments, check-ups, and tests to monitor your health and how you are responding to the treatment. These tests might include blood tests and scans. The exact duration of your involvement will depend on the study's plan and how you react to the treatment, but you will have follow-up visits to track your progress. The study doctors and nurses will explain the full schedule to you.